Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis

被引：24

作者：

Lingscheid, Tilman ^{[1
,2
,3
]}

Kinzig, Martina ^{[4
]}

Krueger, Anne ^{[2
,3
,5
]}

Mueller, Nils ^{[2
,3
,5
]}

Boelke, Georg ^{[2
,3
,5
]}

Tober-Lau, Pinkus ^{[1
,2
,3
]}

Muenn, Friederike ^{[1
,2
,3
]}

Kriedemann, Helene ^{[1
,2
,3
]}

Witzenrath, Martin ^{[1
,2
,3
,6
]}

Sander, Leif E. ^{[1
,2
,3
,6
,7
]}

Soergel, Fritz ^{[4
,8
]}

Kurth, Florian ^{[1
,2
,3
,9
]}

机构：

[1] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany

[2] Free Univ Berlin, Berlin, Germany

[3] Humboldt Univ, Berlin, Germany

[4] IBMP Inst Biomed & Pharmaceut Res, Nurnberg, Germany

[5] Charite Univ Med Berlin, Dept Nephrol & Intens Care, Berlin, Germany

[6] DZL, German Ctr Lung Res, Berlin, Germany

[7] Berlin Inst Hlth, Berlin, Germany

[8] Univ Duisburg Essen, West German Heart & Vasc Ctr, Inst Pharmacol, Essen, Germany

[9] Bernhard Nocht Inst Trop Med, Dept Trop Med, Hamburg, Germany

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2022年 / 66卷 / 11期

关键词：

COVID-19; end-stage renal disease; hemodialysis; nirmatrelvir/ritonavir; Paxlovid; PLASMA;

D O I：

10.1128/aac.01229-22

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data. We investigated the pharmacokinetics of nirmatrelvir/ritonavir (150 mg/100 mg twice a day) in four patients with ESRD undergoing hemodialysis. Nirmatrelvir peak concentrations ranged from 4,563 to 7,898 ng/ mL and declined after hemodialysis. Concentrations were up to 4-fold higher but still within the range known from patients without ESRD, without accumulation of nirmatrelvir after the end of treatment.

引用

页数：4

共 50 条

[41] Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis
Alves Rios, Danyelle Romana
Pinheiro, Melina Barros
de Oliveira Junior, Wander Valadares
Gomes, Karina Braga
Carvalho, Andrea Teixeira
Martins-Filho, Olindo Assis
Simoes e Silva, Ana Cristina
Sant'Ana Dusse, Luci Maria
DISEASE MARKERS, 2017, 2017
[42] Nirmatrelvir/ritonavir well tolerated for COVID-19 in patients with CKD
Reactions Weekly, 2023, 1969 (1) : 12 - 12
[43] The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis
Don, BR
Spin, G
Nestorov, I
Hutmacher, M
Rose, A
Kaysen, GA
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (11) : 1407 - 1413
[44] Prediction of pharmacokinetics of antibiotics in patients with end-stage renal disease
Tajima, Naoyuki
Nagashima, Satoru
Uematsu, Toshihiko
Torii, Hideki
Tajima, Masami
Hishida, Akira
Naganuma, Hideo
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (07) : 1454 - 1459
[45] Pharmacokinetics of Intravenous Delafloxacin in Patients With End-Stage Renal Disease
Hoover, Randall
Alcorn, Harry, Jr.
Lawrence, Laura
Paulson, Susan K.
Quintas, Megan
Cammarata, Sue K.
JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (07): : 913 - 919
[46] One-year all-cause mortality in hospitalized patients with COVID-19 and end-stage renal disease undergoing hemodialysis
Mendoza, Jair Munoz
Aponte-Becerra, Laura
Torres, Carlos
Rozas, Jhoan
Francois, Patrick
Salcedo, Juan
Barreto, Alfredo
Rodriguez, Juanly
Suarez, Maritza
Fornoni, Alessia
Contreras, Gabriel
CLINICAL NEPHROLOGY, 2023, 99 (02) : 51 - 57
[47] Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy
Park, Joon-Sung
Minn, Dohsik
Hong, Susie
Jeong, Saeyoung
Kim, Soohyun
Lee, Chang Hwa
Kim, Bongyoung
JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (23)
[48] Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis
Lorusso, V
Taroni, P
Alvino, S
Spinazzi, A
INVESTIGATIVE RADIOLOGY, 2001, 36 (06) : 309 - 316
[49] Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
Xu, Ping
Zhang, Lijun
Wu, Qingguo
BMC INFECTIOUS DISEASES, 2024, 24 (01)
[50] Hemodialysis in children with end-stage renal disease
Dominik Müller
Stuart L. Goldstein
Nature Reviews Nephrology, 2011, 7 : 650 - 658

← 1 2 3 4 5 →